Michelle Paula McIntosh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3164259/publications.pdf

Version: 2024-02-01

65 papers

2,186 citations

257357 24 h-index 233338 45 g-index

65 all docs

65 docs citations

65 times ranked

2783 citing authors

#	Article	IF	Citations
1	Depolymerization of hyaluronan using PEGylated human recombinant hyaluronidase promotes nanoparticle tumor penetration. Nanomedicine, 2021, 16, 275-292.	1.7	5
2	Global testing of a consensus solubility assessment to enhance robustness of the WHO biopharmaceutical classification system. ADMET and DMPK, 2021, 9, 23-39.	1.1	7
3	Qualitative formative implementation research to inform introduction of a new essential medicine. Research in Social and Administrative Pharmacy, 2020, 16, 535-543.	1.5	2
4	The impact of size and charge on the pulmonary pharmacokinetics and immunological response of the lungs to PLGA nanoparticles after intratracheal administration to rats. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 30, 102291.	1.7	22
5	Cost-effectiveness of inhaled oxytocin for prevention of postpartum haemorrhage: a modelling study applied to two high burden settings. BMC Medicine, 2020, 18, 201.	2.3	4
6	Oxytocin quality: evidence to support updated global recommendations on oxytocin for postpartum hemorrhage. Journal of Pharmaceutical Policy and Practice, 2020, 13, 14.	1.1	9
7	Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats. Journal of Controlled Release, 2019, 315, 85-96.	4.8	10
8	Local inflammation alters the lung disposition of a drug loaded pegylated liposome after pulmonary dosing to rats. Journal of Controlled Release, 2019, 307, 32-43.	4.8	26
9	Temperature stability of oxytocin ampoules labelled for storage at 2°C–8°C and below 25°C: an observational assessment under controlled accelerated and temperature cycling conditions. BMJ Open, 2019, 9, e029083.	0.8	10
10	Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model. Journal of Antimicrobial Chemotherapy, 2018, 73, 1570-1578.	1.3	21
11	A comparison of the lung clearance kinetics of solid lipid nanoparticles and liposomes by following the 3H-labelled structural lipids after pulmonary delivery in rats. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 125, 1-12.	2.0	42
12	Assessing the operational feasibility and acceptability of an inhalable formulation of oxytocin for improving community-based prevention of postpartum haemorrhage in Myanmar: a qualitative inquiry. BMJ Open, 2018, 8, e022140.	0.8	4
13	Knowledge, perception and practice towards oxytocin stability and quality: A qualitative study of stakeholders in three resource-limited countries. PLoS ONE, 2018, 13, e0203810.	1.1	20
14	Suggested Procedures for the Reproducible Synthesis of Poly(d,l-lactideco-glycolide) Nanoparticles Using the Emulsification Solvent Diffusion Platform. Current Nanoscience, 2018, 14, 448-453.	0.7	25
15	Quality of oxytocin ampoules available in health care facilities in the Democratic Republic of Congo: an exploratory study in five provinces. Journal of Global Health, 2018, 8, 020415.	1.2	12
16	Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	27
17	Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 119, 408-418.	2.0	28
18	Safety, Tolerability and Pharmacokinetics of Single Doses of Oxytocin Administered via an Inhaled Route in Healthy Females: Randomized, Single-blind, Phase 1 Study. EBioMedicine, 2017, 22, 249-255.	2.7	17

#	Article	IF	CITATIONS
19	Comb Poly(Oligo(2â€Ethylâ€2â€Oxazoline)Methacrylate)â€Peptide Conjugates Prepared by Aqueous Cu(0)â€Mediated Polymerization and Reductive Amination. Macromolecular Rapid Communications, 2017, 38, 1600534.	2.0	22
20	Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of <i> Pseudomonas aeruginosa </i> , but do not suppress the emergence of fosfomycin resistance. Journal of Antimicrobial Chemotherapy, 2016, 71, 2218-2229.	1.3	32
21	Stability Enhancing <i>N</i> -Terminal PEGylation of Oxytocin Exploiting Different Polymer Architectures and Conjugation Approaches. Biomacromolecules, 2016, 17, 2755-2766.	2.6	13
22	Disposition and safety of inhaled biodegradable nanomedicines: Opportunities and challenges. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1703-1724.	1.7	67
23	Designing a multi-component spray-dried formulation platform for pulmonary delivery of biopharmaceuticals: The use of polyol, disaccharide, polysaccharide and synthetic polymer to modify solid-state properties for glassy stabilisation. Powder Technology, 2016, 287, 248-255.	2.1	20
24	Evaluation of the Impact of Sulfobutylether $7 \cdot \hat{l}^2$ -Cydodextrin on the Liquid Chromatography-Mass spectrometry Analysis of Biological Samples Arising from In Vivo Pharmacokinetic Studies. Journal of Pharmaceutical Sciences, 2015, 104, 1561-1562.	1.6	2
25	The Effect of Intravenous Sulfobutylether7-β-Cyclodextrin on the Pharmacokinetics of a Series of Adamantane-Containing Compounds. Journal of Pharmaceutical Sciences, 2015, 104, 1492-1498.	1.6	17
26	Spray-Dried Influenza Antigen with Trehalose and Leucine Produces an Aerosolizable Powder Vaccine Formulation that Induces Strong Systemic and Mucosal Immunity after Pulmonary Administration. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2015, 28, 361-371.	0.7	42
27	In Situ Conjugation of Dithiophenol Maleimide Polymers and Oxytocin for Stable and Reversible Polymer–Peptide Conjugates. Bioconjugate Chemistry, 2015, 26, 633-638.	1.8	47
28	<i>In vitro</i> pharmacodynamics of fosfomycin against clinical isolates of <i>Pseudomonas aeruginosa</i> . Journal of Antimicrobial Chemotherapy, 2015, 70, 3042-3050.	1.3	72
29	The Lymphatic System Plays a Major Role in the Intravenous and Subcutaneous Pharmacokinetics of Trastuzumab in Rats. Molecular Pharmaceutics, 2014, 11, 496-504.	2.3	49
30	Effective pulmonary delivery of an aerosolized plasmid DNA vaccine via surface acoustic wave nebulization. Respiratory Research, 2014, 15, 60.	1.4	81
31	Pulmonary and Systemic Pharmacokinetics of Inhaled and Intravenous Colistin Methanesulfonate in Cystic Fibrosis Patients: Targeting Advantage of Inhalational Administration. Antimicrobial Agents and Chemotherapy, 2014, 58, 2570-2579.	1.4	138
32	Pulmonary Administration of PEGylated Polylysine Dendrimers: Absorption from the Lung versus Retention within the Lung Is Highly Size-Dependent. Molecular Pharmaceutics, 2013, 10, 2986-2995.	2.3	93
33	Designing a Multicomponent Spray-Dried Formulation Platform for Pulmonary Delivery of Biomacromolecules: The Effect of Polymers on the Formation of an Amorphous Matrix for Glassy State Stabilization of Biomacromolecules. Drying Technology, 2013, 31, 1451-1458.	1.7	20
34	Population Pharmacokinetics of Colistin Methanesulfonate in Rats: Achieving Sustained Lung Concentrations of Colistin for Targeting Respiratory Infections. Antimicrobial Agents and Chemotherapy, 2013, 57, 5087-5095.	1.4	42
35	PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin. Journal of Controlled Release, 2013, 172, 128-136.	4.8	74
36	The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 83, 234-243.	2.0	115

#	Article	IF	CITATIONS
37	Effect of Freezing on Oxytocin Ampules. New England Journal of Medicine, 2013, 368, 2145-2146.	13.9	25
38	Pulmonary Delivery of an Ultra-Fine Oxytocin Dry Powder Formulation: Potential for Treatment of Postpartum Haemorrhage in Developing Countries. PLoS ONE, 2013, 8, e82965.	1.1	20
39	Lipid Digestion as a Trigger for Supersaturation: Evaluation of the Impact of Supersaturation Stabilization on the in Vitro and in Vivo Performance of Self-Emulsifying Drug Delivery Systems. Molecular Pharmaceutics, 2012, 9, 2063-2079.	2.3	125
40	Hemodynamic Profile in Rabbits of Fospropofol Disodium Injection Relative to Propofol Emulsion Following Rapid Bolus Injection. Journal of Pharmaceutical Sciences, 2012, 101, 3518-3525.	1.6	5
41	Probing a Potential In Vivo Drug–Excipient Interaction: Temporal Effects of a Modified β-Cyclodextrin on the Intravenous Pharmacokinetics of a Model High-Affinity Drug Ligand. Journal of Pharmaceutical Sciences, 2012, 101, 3381-3389.	1.6	3
42	Comparative canine Pharmacokinetics–Pharmacodynamics of Fospropofol Disodium Injection, Propofol Eemulsion, and Cyclodextrin-Enabled Propofol Solution Following Bolus Parenteral Administration. Journal of Pharmaceutical Sciences, 2012, 101, 3547-3552.	1.6	19
43	New developments in dry powder pulmonary vaccine delivery. Trends in Biotechnology, 2011, 29, 191-198.	4.9	109
44	Investigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery: A design of experiment approach. International Journal of Pharmaceutics, 2011, 421, 220-229.	2.6	51
45	Structural influence of cohesive mixtures of salbutamol sulphate and lactose on aerosolisation and de-agglomeration behaviour under dynamic conditions. European Journal of Pharmaceutical Sciences, 2011, 42, 210-219.	1.9	22
46	Evaluation of the impact of altered lipoprotein binding conditions on halofantrine induced QTc interval prolongation in an anaesthetized rabbit modelâ€. Journal of Pharmacy and Pharmacology, 2010, 56, 69-77.	1.2	48
47	The Role of the Intestinal Lymphatics in the Absorption of Two Highly Lipophilic Cholesterol Ester Transfer Protein Inhibitors (CP524,515 and CP532,623). Pharmaceutical Research, 2010, 27, 878-893.	1.7	35
48	Preclinical comparison of intravenous melphalan pharmacokinetics administered in formulations containing either (SBE) _{7 m} â€ <i>β</i> yclodextrin or a coâ€solvent system. Biopharmaceutic and Drug Disposition, 2010, 31, 450-454.	281.1	12
49	Impact of Chlorpromazine Self-Association on Its Apparent Binding Constants With Cyclodextrins: Effect of SBE7-Î ² -CD on the Disposition of Chlorpromazine in the Rat. Journal of Pharmaceutical Sciences, 2010, 99, 2999-3008.	1.6	10
50	Ultrasonic nebulization platforms for pulmonary drug delivery. Expert Opinion on Drug Delivery, 2010, 7, 663-679.	2.4	106
51	Inhibiting Heat-Shock Protein 90 Reverses Sensory Hypoalgesia in Diabetic Mice. ASN Neuro, 2010, 2, AN20100015.	1.5	67
52	Miniature inhalation therapy platform using surface acoustic wave microfluidic atomization. Lab on A Chip, 2009, 9, 2184.	3.1	151
53	Single quadrupole mass spectrometry for pre-clinical pharmacokinetic analysis: Quantitation of carvedilol in dog plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 852, 665-668.	1.2	9
54	Evaluation of mean arterial blood pressure, heart rate, and sympathetic nerve activity in rabbits after administration of two formulations of etomidate. Veterinary Anaesthesia and Analgesia, 2007, 34, 149-156.	0.3	6

#	Article	IF	CITATIONS
55	Preparation and Purification of Desethylamiodarone Hydrochloride. Synthetic Communications, 2006, 36, 3371-3376.	1.1	3
56	Preliminary Evaluation of Polymer-Based Drug Composite Microparticle Production by Coacervate Desolvation with Supercritical Carbon Dioxide. Journal of Pharmaceutical Sciences, 2006, 95, 581-588.	1.6	5
57	Ongoing In Vivo Studies with Cytoskeletal Drugs in Tau Transgenic Mice. Current Alzheimer Research, 2006, 3, 215-219.	0.7	12
58	Influence of physicochemical properties on the patterns of association of a series of aliphatic esters of halofantrine with plasma lipoproteins. Journal of Controlled Release, 2004, 95, 275-289.	4.8	6
59	In vitro and in vivo evaluation of a sulfobutyl ether βâ€cyclodextrin enabled etomidate formulation. Journal of Pharmaceutical Sciences, 2004, 93, 2585-2594.	1.6	33
60	Desbutylhalofantrine: Evaluation of QT Prolongation and Other Cardiovascular Effects after Intravenous Administration In Vivo. Journal of Cardiovascular Pharmacology, 2003, 41, 406-413.	0.8	11
61	A simple and efficient high-performance liquid chromatographic assay for etomidate in plasma. Journal of Pharmaceutical and Biomedical Analysis, 2001, 24, 689-694.	1.4	14
62	Differences in the Lipoprotein Binding profile of Halofantrine in Fed and Fasted Human or beagle Plasma are dictated by the Respective Masses of Core Apolar Lipoprotein Lipid. Journal of Pharmaceutical Sciences, 1999, 88, 378-384.	1.6	22
63	Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: In vitro studies in normolipidemic and dyslipidemic human plasmas. Journal of Pharmaceutical Sciences, 1999, 88, 185-190.	1.6	20
64	Pharmacokinetics and Safety of Inhaled Oxytocin Compared with Intramuscular Oxytocin: The First Randomised Open-Label Study in Women in the Third Stage of Labour. SSRN Electronic Journal, 0, , .	0.4	0
65	Oxytocin injection quality in Ethiopia: a post-marketing surveillance study in public and private facilities across three regions. Journal of Forensic Odonto-Stomatology, 0, 3, .	0.2	0